Jiangyin International: Firmly optimistic about AKESO, recommended buy rating, target price HKD 183
Jiangyin International released a research report stating that it maintains a target price of HKD 183 for AKESO, with a long-term positive outlook and a recommendation to "buy." The report indicates that the company's overseas development is gaining momentum, with a concentration of catalysts expected in the next 1-2 years. Meanwhile, Summit Therapeutics recently announced an expansion of the overseas research scale for Evosap. The report noted that the second head-to-head PD-1 Phase III study for Evosap has yielded strong positive data, with non-head-to-head comparisons showing that the median PFS value for Evosap is significantly better than other PD-1 monotherapy drugs, and the absolute improvement in PFS compared to PD-1 has exceeded the improvement level of PD-1 compared to traditional chemotherapy. The report maintains the expectation of peak sales in mainland China at RMB 7.1 billion
According to Zhitong Finance APP, Jiangyin International released a research report stating that it maintains a target price of HKD 183 for AKESO (09926), and is long-term optimistic with a "Buy" rating. The bank indicated that the company's overseas development is gradually improving, with a dense pipeline of catalysts expected in the next 1-2 years. Meanwhile, Summit Therapeutics recently announced the expansion of the overseas research scale of Evosap.
The report stated that the second head-to-head Phase III study of Evosap has again yielded strong positive data, with non-head-to-head comparisons showing that the median PFS value of Evosap is significantly better than that of other PD-1 monotherapy drugs, and the absolute improvement in PFS compared to PD-1 has exceeded the improvement level of PD-1 compared to traditional chemotherapy. The bank maintains its expectation of peak sales in mainland China at RMB 7.1 billion
